Lipid Panel

Close-up of clinical laboratory blood draw for Lipid Panel testing
Close-up of clinical laboratory blood draw for Lipid Panel testing.
Microscopic view of biological markers measured in Lipid Panel
Microscopic view of biological markers measured in Lipid Panel.
Anatomical illustration of organ or tissue revealed by Lipid Panel
Anatomical illustration of organ or tissue revealed by Lipid Panel.
🧈 Interactive Visualization Cholesterol & the Artery Wall — watch a plaque form Follow low-density lipoprotein (LDL) particles into the artery wall and see foam cells build plaque — then add a statin and watch the receptors clear them. Launch →

Table of Contents

Overview: What the Lipid Panel Measures

The lipid panel, also called a lipid profile or lipid screen, is one of the most commonly ordered blood tests in clinical practice. It provides a snapshot of the fats and fat-like substances circulating in the bloodstream. A standard lipid panel typically measures four primary markers: total cholesterol, low-density lipoprotein cholesterol (low-density lipoprotein), high-density lipoprotein (HDL) cholesterol, and triglycerides. Some laboratories also calculate very-low-density lipoprotein (VLDL) cholesterol (very low-density lipoprotein) as part of the standard report.

From a functional medicine perspective, the lipid panel is a starting point, not an endpoint, for assessing cardiovascular risk. While conventional medicine often focuses narrowly on low-density lipoprotein cholesterol as the primary driver of heart disease, a naturopathic and functional approach recognizes that lipid metabolism is far more nuanced. The context in which these numbers exist matters tremendously: inflammation, insulin resistance, thyroid function, nutrient status, and oxidative stress all influence what the lipid numbers actually mean for an individual patient.

The test is typically performed after a 9 to 12 hour fast, though recent guidelines suggest that non-fasting samples may be acceptable for initial screening. Fasting samples remain the gold standard for accurate triglyceride measurement and for calculating low-density lipoprotein cholesterol using the Friedewald equation. Blood is drawn from a vein, usually in the arm, and results are generally available within 24 to 48 hours.

Total Cholesterol: Conventional vs Functional Optimal Ranges

Total cholesterol represents the sum of all cholesterol carried in the blood, including low-density lipoprotein, high-density lipoprotein, very-low-density lipoprotein, and other lipoprotein fractions. Conventional medicine classifies total cholesterol as follows:

However, these cutoffs deserve scrutiny. From a functional medicine standpoint, an optimal total cholesterol range is often considered to be between 180 and 250 mg/dL, depending on the full clinical picture. Total cholesterol below 150 mg/dL has been associated with increased risk of depression, hormonal insufficiency, cognitive decline, and even increased mortality in elderly populations. Cholesterol is not merely a harmful substance to be driven as low as possible. It is a vital building block for cell membranes, a precursor for steroid hormones (including cortisol, estrogen, progesterone, testosterone, and DHEA), a precursor for vitamin D synthesis, and an essential component of bile acids needed for fat digestion and detoxification.

Why total cholesterol alone is misleading: A person with a total cholesterol of 240 mg/dL who has high high-density lipoprotein, low triglycerides, and predominantly large buoyant low-density lipoprotein particles may have a far lower cardiovascular risk than someone with a total cholesterol of 190 mg/dL who has low high-density lipoprotein, high triglycerides, and small dense low-density lipoprotein particles. Total cholesterol is simply too blunt a measurement to serve as a reliable standalone indicator of heart disease risk. The composition and context of the cholesterol matter far more than the aggregate number.

It is also worth noting that total cholesterol naturally rises with age, particularly in women after menopause, and may fluctuate with seasons, stress levels, acute illness, and thyroid function. A single elevated reading should always be confirmed and interpreted within the broader clinical context.

Low-Density Lipoprotein Cholesterol: Calculated vs Direct and Particle Size

Low-density lipoprotein cholesterol has been labeled "bad cholesterol" in popular discourse, but this oversimplification obscures critical nuances. On a standard lipid panel, low-density lipoprotein is typically not measured directly. Instead, it is calculated using the Friedewald equation:

Low-density lipoprotein = Total Cholesterol - high-density lipoprotein - (Triglycerides / 5)

This calculation becomes increasingly inaccurate when triglycerides exceed 200 mg/dL and is considered unreliable above 400 mg/dL. In patients with high triglycerides, the calculated low-density lipoprotein may significantly underestimate or overestimate the true low-density lipoprotein value. Direct low-density lipoprotein measurement is available and should be considered when triglycerides are elevated or when more precision is needed.

Conventional reference ranges for low-density lipoprotein cholesterol include:

Functional medicine practitioners often consider an optimal low-density lipoprotein range of 80 to 130 mg/dL, recognizing that very low low-density lipoprotein levels may carry their own risks, including impaired hormone production and immune function.

Particle Size Matters: Small Dense vs Large Buoyant Low-Density Lipoprotein

Perhaps the most important insight from modern lipid research is that not all low-density lipoprotein particles are created equal. Low-density lipoprotein particles exist on a spectrum from small, dense particles (Pattern B) to large, buoyant particles (Pattern A):

Standard lipid panels do not differentiate between these particle types. Advanced testing through NMR LipoProfile or ion mobility analysis is required to determine low-density lipoprotein particle size distribution. This distinction is one of the primary reasons why the standard lipid panel, taken in isolation, can be a poor predictor of cardiovascular events.

High-Density Lipoprotein Cholesterol: The Protective Lipoprotein

High-density lipoprotein cholesterol is often called "good cholesterol" because of its role in reverse cholesterol transport, the process by which excess cholesterol is removed from arterial walls and peripheral tissues and transported back to the liver for recycling or excretion. High-density lipoprotein also possesses anti-inflammatory, antioxidant, and anticlotting properties that contribute to cardiovascular protection.

Conventional reference ranges classify high-density lipoprotein as follows:

From a functional medicine perspective, optimal high-density lipoprotein levels are generally considered to be 55 to 70 mg/dL for men and 65 to 80 mg/dL for women. Extremely high high-density lipoprotein (above 90 to 100 mg/dL) is not always protective and may in some cases reflect dysfunctional high-density lipoprotein that has lost its anti-inflammatory and reverse transport capacity. Recent research has identified that high-density lipoprotein functionality, not just high-density lipoprotein quantity, determines its protective value.

Low high-density lipoprotein is one of the most consistent markers of metabolic dysfunction and is frequently seen alongside insulin resistance, central obesity, sedentary lifestyle, smoking, and a diet high in refined carbohydrates and trans fats. Raising high-density lipoprotein through lifestyle interventions is far more effective and beneficial than pharmaceutical approaches. Regular aerobic exercise, moderate alcohol consumption, adequate omega-3 fatty acid intake, and weight loss are among the most effective strategies for increasing high-density lipoprotein levels naturally.

Triglycerides: A Window into Metabolic Health

Triglycerides are the most abundant form of fat in the body and serve as a major energy storage molecule. They are formed from dietary fats as well as from excess carbohydrates, sugars, and alcohol that the liver converts into fat. Triglyceride levels are perhaps the most metabolically revealing number on the standard lipid panel.

Conventional reference ranges for triglycerides:

Functional medicine optimal range for triglycerides is significantly tighter: 50 to 100 mg/dL. Levels above 100 mg/dL begin to suggest metabolic inefficiency, and levels above 150 mg/dL are a strong signal of insulin resistance, even when fasting glucose appears normal.

The Link to Insulin Resistance

Elevated triglycerides are one of the earliest and most sensitive markers of insulin resistance and metabolic syndrome. When cells become resistant to insulin, the liver compensates by producing more very-low-density lipoprotein particles (which carry triglycerides), leading to elevated circulating triglyceride levels. This relationship is so consistent that triglyceride levels are often used as a surrogate marker for insulin sensitivity in clinical practice.

The dietary driver of elevated triglycerides is overwhelmingly excess carbohydrate intake, particularly refined carbohydrates, sugar, fructose, and alcohol, rather than dietary fat. This is a critical distinction that conventional dietary advice has historically gotten backwards. Reducing refined carbohydrates and sugars is typically the single most effective intervention for lowering triglycerides, often producing dramatic reductions within weeks.

Triglyceride levels above 500 mg/dL carry a risk of acute pancreatitis and require more urgent intervention. Other causes of elevated triglycerides include hypothyroidism, kidney disease, certain medications (including beta-blockers, thiazide diuretics, oral estrogen, and retinoids), and genetic conditions such as familial hypertriglyceridemia.

Very-Low-Density Lipoprotein Cholesterol

Very-low-density lipoprotein (very low-density lipoprotein) is produced by the liver and serves as the primary vehicle for transporting triglycerides from the liver to peripheral tissues. Very-low-density lipoprotein particles are triglyceride-rich and, as they deliver their triglyceride cargo, they are progressively converted into intermediate-density lipoprotein (IDL) and eventually into low-density lipoprotein particles.

On a standard lipid panel, very-low-density lipoprotein is typically estimated rather than directly measured, using the formula:

Very-low-density lipoprotein = Triglycerides / 5

The conventional normal range for very-low-density lipoprotein is 5 to 30 mg/dL. Functional optimal is generally considered to be below 20 mg/dL. Because very-low-density lipoprotein is derived from triglycerides, elevated very-low-density lipoprotein tracks closely with elevated triglycerides and carries the same metabolic implications regarding insulin resistance and carbohydrate metabolism.

Very-low-density lipoprotein remnant particles are increasingly recognized as independently atherogenic. These remnant particles can penetrate the arterial wall and contribute to plaque formation. Elevated very-low-density lipoprotein and remnant cholesterol may help explain cardiovascular events that occur in patients whose low-density lipoprotein appears to be at goal, a phenomenon sometimes called "residual risk."

Key Ratios: What They Reveal About Cardiovascular Risk

While individual lipid values provide useful information, certain ratios derived from the lipid panel are often more predictive of cardiovascular risk than any single number. Functional medicine practitioners routinely calculate and monitor these ratios.

Triglyceride to High-Density Lipoprotein Ratio (TG/HDL)

The triglyceride to high-density lipoprotein ratio is arguably the single most useful number that can be derived from a standard lipid panel. It serves as a powerful surrogate marker for insulin resistance, low-density lipoprotein particle size, and cardiovascular risk:

A TG/HDL ratio below 2.0 strongly predicts large buoyant low-density lipoprotein particle predominance (Pattern A), while a ratio above 3.0 strongly predicts small dense low-density lipoprotein predominance (Pattern B). This simple calculation provides insight into low-density lipoprotein particle size without the need for expensive advanced testing and is one of the most cost-effective tools in cardiovascular risk assessment.

Total Cholesterol to High-Density Lipoprotein Ratio (TC/HDL)

The total cholesterol to high-density lipoprotein ratio provides a broader view of lipid balance and cardiovascular risk:

This ratio captures the balance between potentially atherogenic lipoproteins and protective high-density lipoprotein. A person with a total cholesterol of 250 mg/dL and a high-density lipoprotein of 80 mg/dL (ratio of 3.1) is at considerably lower risk than a person with total cholesterol of 200 mg/dL and a high-density lipoprotein of 35 mg/dL (ratio of 5.7).

Low-Density Lipoprotein to High-Density Lipoprotein Ratio

The low-density lipoprotein to high-density lipoprotein ratio offers another lens on atherogenic risk. An optimal low-density lipoprotein/high-density lipoprotein ratio is below 2.5 for men and below 2.0 for women. Values above 3.5 indicate significant cardiovascular risk regardless of individual low-density lipoprotein or high-density lipoprotein values.

Advanced Lipid Testing: Beyond the Standard Panel

When a more detailed assessment of cardiovascular risk is needed, advanced lipid testing provides information that the standard panel simply cannot capture. Functional medicine practitioners frequently order these tests, particularly for patients with a family history of heart disease, metabolic syndrome, or lipid values that do not seem to match their clinical picture.

Low-Density Lipoprotein Particle Number (Low-Density Lipoprotein-P)

Low-density lipoprotein particle number measures the actual count of low-density lipoprotein particles circulating in the blood, as opposed to the cholesterol content carried within those particles (which is what standard low-density lipoprotein cholesterol (LDL-C) measures). Research has consistently shown that low-density lipoprotein-P is a stronger predictor of cardiovascular events than low-density lipoprotein cholesterol. Two patients can have identical low-density lipoprotein cholesterol values yet dramatically different low-density lipoprotein-P counts, leading to very different risk profiles. An optimal low-density lipoprotein-P is generally below 1000 nmol/L, with levels above 1300 nmol/L indicating elevated risk. Low-density lipoprotein-P is measured via NMR LipoProfile testing.

Lipoprotein(a) - Lp(a)

Lipoprotein(a) is a genetically determined lipoprotein that is structurally similar to low-density lipoprotein but includes an additional protein called apolipoprotein(a). Elevated Lp(a) is an independent and potent risk factor for atherosclerosis, heart attack, stroke, and aortic valve stenosis. Lp(a) levels are largely determined by genetics and are minimally affected by diet or lifestyle interventions. Approximately 20 percent of the population carries elevated Lp(a). Optimal levels are below 30 mg/dL (or below 75 nmol/L). Because Lp(a) is genetically fixed, it only needs to be tested once in a lifetime, though knowing your level is essential for comprehensive risk assessment. Niacin (vitamin B3) is one of the few agents that has been shown to modestly reduce Lp(a).

Apolipoprotein B (ApoB)

ApoB is the primary protein found on all atherogenic lipoprotein particles, including low-density lipoprotein, VLDL, IDL, and Lp(a). Because each atherogenic particle contains exactly one ApoB molecule, ApoB provides a direct count of total atherogenic particles. Many researchers and clinicians now consider ApoB to be the single best lipid-related predictor of cardiovascular risk. Optimal ApoB levels are below 80 mg/dL, with levels above 100 mg/dL indicating elevated risk.

Oxidized Low-Density Lipoprotein (OxLDL)

Oxidized low-density lipoprotein represents low-density lipoprotein particles that have undergone oxidative damage. It is oxidized low-density lipoprotein, not native low-density lipoprotein, that triggers the inflammatory cascade leading to atherosclerotic plaque formation. When low-density lipoprotein particles become oxidized, they are taken up by macrophages in the arterial wall, forming foam cells, which are the hallmark of early atherosclerosis. Measuring oxidized low-density lipoprotein provides direct insight into the degree of oxidative stress affecting lipid metabolism. Elevated oxidized low-density lipoprotein suggests the need for antioxidant support, anti-inflammatory strategies, and investigation of oxidative stress sources such as smoking, environmental toxins, poor diet, and chronic infection.

The Cholesterol Controversy: Rethinking the Narrative

The conventional narrative that high cholesterol directly causes heart disease has been increasingly challenged by researchers and clinicians over the past two decades. While there is no doubt that atherosclerosis involves cholesterol deposition in arterial walls, the simplistic model of "high cholesterol equals heart disease" fails to account for numerous observations and contradictions in the scientific literature.

Why High Cholesterol Is Not Always Bad

Multiple large epidemiological studies have demonstrated that in elderly populations (over age 60 to 65), higher total cholesterol is paradoxically associated with lower all-cause mortality. This "cholesterol paradox" has been observed in studies from Japan, Europe, and the United States. Additionally, roughly half of all heart attacks occur in people with normal or low cholesterol levels, and many people with elevated cholesterol never develop heart disease.

Cholesterol serves essential physiological functions that must not be overlooked:

The Role of Inflammation

A growing body of evidence suggests that chronic inflammation, not cholesterol per se, is the primary driver of atherosclerotic cardiovascular disease. Cholesterol becomes problematic primarily when it is deposited in arterial walls that are already inflamed and damaged. The inflammatory model of heart disease explains why markers like high-sensitivity C-reactive protein (hs-CRP), homocysteine, fibrinogen, and oxidized low-density lipoprotein are often better predictors of cardiovascular events than low-density lipoprotein cholesterol alone.

From a naturopathic perspective, addressing the root causes of inflammation (including poor diet, blood sugar dysregulation, chronic infections, environmental toxins, stress, and gut dysbiosis) is a more rational and effective strategy for reducing cardiovascular risk than simply driving cholesterol numbers down with medication.

Natural Strategies for Improving Lipid Markers

Naturopathic and functional medicine offer a rich array of evidence-based strategies for optimizing lipid profiles. These interventions address root causes rather than merely suppressing numbers, and they often improve the overall metabolic landscape simultaneously.

Omega-3 Fatty Acids

Omega-3 fatty acids (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) from fish oil or algae-based sources are among the most effective natural interventions for lipid optimization. They lower triglycerides by 15 to 30 percent at therapeutic doses (2 to 4 grams of combined eicosapentaenoic acid/docosahexaenoic acid daily), reduce inflammation, decrease oxidized low-density lipoprotein, improve high-density lipoprotein functionality, and shift low-density lipoprotein particle size toward the large buoyant pattern. Wild-caught fatty fish (salmon, sardines, mackerel, anchovies) consumed 3 to 4 times weekly also provides significant benefit.

Niacin (Vitamin B3)

Niacin is the most effective natural agent for raising high-density lipoprotein cholesterol, with increases of 15 to 35 percent at therapeutic doses (1000 to 2000 mg daily of immediate-release or extended-release formulations). Niacin also lowers triglycerides by 20 to 50 percent, reduces low-density lipoprotein particle number, shifts low-density lipoprotein toward the large buoyant pattern, and is one of the few substances that lowers Lp(a) by 10 to 30 percent. The flushing side effect can be mitigated by starting with low doses and gradually titrating upward, taking with food, and using extended-release formulations. Niacin should be monitored with liver function tests when used at therapeutic doses.

Soluble Fiber

Soluble fiber from sources such as oats, psyllium husk, ground flaxseed, chia seeds, beans, lentils, and vegetables binds bile acids in the gut, forcing the liver to use cholesterol to make new bile acids and thereby lowering circulating low-density lipoprotein by 5 to 15 percent. A daily intake of 10 to 25 grams of soluble fiber is recommended. Psyllium husk (5 to 10 grams daily) is a convenient supplemental option.

Exercise

Regular physical activity is one of the most powerful interventions for lipid optimization. Aerobic exercise raises high-density lipoprotein by 5 to 15 percent, lowers triglycerides by 10 to 30 percent, shifts low-density lipoprotein toward the large buoyant pattern, and improves insulin sensitivity. Both moderate-intensity continuous training (brisk walking, cycling, swimming for 150 or more minutes per week) and high-intensity interval training (HIIT) have demonstrated significant lipid benefits. Resistance training also contributes to improved metabolic health and lipid profiles.

Reducing Refined Carbohydrates and Sugar

Excess refined carbohydrate and sugar consumption is the single greatest dietary driver of dyslipidemia, particularly the pattern of high triglycerides, low high-density lipoprotein, and small dense low-density lipoprotein known as atherogenic dyslipidemia. Reducing or eliminating refined grains, added sugars, high-fructose corn syrup, fruit juice, and excess alcohol produces rapid and often dramatic improvements in triglycerides and high-density lipoprotein. A whole-foods diet emphasizing vegetables, quality proteins, healthy fats, nuts, seeds, and moderate amounts of whole grains and fruit provides the foundation for optimal lipid metabolism.

Additional Natural Interventions

Statin Considerations: Weighing Benefits and Risks

Statin medications (atorvastatin, rosuvastatin, simvastatin, pravastatin, and others) are the most widely prescribed class of cholesterol-lowering drugs. They work by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. While statins effectively lower low-density lipoprotein cholesterol by 30 to 50 percent or more, their use requires careful consideration of both benefits and risks.

Potential benefits of statins: Statins have demonstrated the clearest benefit in secondary prevention, meaning in patients who have already had a cardiovascular event (heart attack, stroke, or documented atherosclerotic disease). In this population, the evidence for reduced recurrence and mortality is robust. Much of this benefit may stem from statins' anti-inflammatory properties rather than their cholesterol-lowering effect per se. For primary prevention (people who have not yet had an event), the benefit is considerably more modest, particularly in women and the elderly.

Potential risks and side effects include:

A thorough shared decision-making process between practitioner and patient should weigh the individual's specific risk factors, the magnitude of expected benefit, the potential for side effects, and whether lifestyle and natural interventions have been adequately explored before initiating statin therapy. In many cases, particularly for primary prevention in lower-risk individuals, aggressive lifestyle modification and targeted supplementation can achieve meaningful lipid improvement without the need for pharmaceutical intervention.

When to Retest

The timing of lipid panel retesting depends on the clinical scenario and the interventions being employed:

For the most accurate results, maintain consistent conditions between tests: fast for 9 to 12 hours, avoid alcohol for 24 to 48 hours prior, avoid vigorous exercise for 24 hours prior, and draw at approximately the same time of day. Acute illness, surgery, or major physiological stress can temporarily alter lipid values. Wait at least 6 weeks after an acute event before drawing lipids.

For a comprehensive cardiovascular and metabolic risk assessment, the lipid panel should be interpreted alongside several complementary tests:

By combining the standard lipid panel with advanced lipid markers, inflammatory markers, and metabolic indicators, a truly comprehensive picture of cardiovascular risk emerges, one that goes far beyond the reductive approach of treating a single low-density lipoprotein number.

Back to Table of Contents

Key Research Papers

The following are curated PubMed literature searches covering the evidence base for lipid panel testing, interpretation, and clinical management. Each link opens a live, filtered PubMed query so the results stay current as new studies are indexed.

  1. LDL cholesterol cardiovascular risk — PubMed literature search
  2. HDL cholesterol function — PubMed literature search
  3. Triglycerides cardiovascular disease — PubMed literature search
  4. Small dense LDL particles — PubMed literature search
  5. Friedewald equation LDL — PubMed literature search
  6. Non-HDL cholesterol prognosis — PubMed literature search
  7. Triglyceride HDL ratio insulin — PubMed literature search
  8. Statin primary prevention — PubMed literature search
  9. PCSK9 inhibitor trials — PubMed literature search
  10. Saturated fat cardiovascular — PubMed literature search

External Authoritative Resources

  1. MedlinePlus — Laboratory Tests Reference
  2. MedlinePlus — Medical Tests (U.S. National Library of Medicine)
  3. MedlinePlus — Medical Tests (U.S. National Library of Medicine)

Back to Table of Contents

Connections

Back to Table of Contents

Lipid Panel — scientific infographic poster